| An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection (NCT04486872) | First Affiliated Hospital of Zhejiang University | 2020-07-25 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (NCT04476459) | Huiqiang Huang | 2020-07-23 |
| CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma (NCT04812691) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2020-07-10 |
| A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). (NCT04236141) | Hoffmann-La Roche | 2020-07-10 |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200) | Memorial Sloan Kettering Cancer Center | 2020-07-06 |
| Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL (NCT04491721) | Chinese Academy of Medical Sciences | 2020-07-01 |
| Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (NCT04263584) | University Hospital Muenster | 2020-06-19 |
| CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT04381741) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-06-18 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956) | Mayo Clinic | 2020-06-15 |
| Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma (NCT04425824) | Chinese Academy of Medical Sciences | 2020-06-15 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (NCT04279405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-06-15 |
| Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma (NCT04432402) | The First Affiliated Hospital with Nanjing Medical University | 2020-06-14 |
| the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy (NCT04914143) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-06-06 |
| Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma (NCT04423549) | Sun Yat-sen University | 2020-06-01 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (NCT04231448) | Chipscreen Biosciences, Ltd. | 2020-05-21 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520) | Medical College of Wisconsin | 2020-05-18 |
| Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) (NCT04300101) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2020-05-14 |
| A Study of ICP-022 in Patients With R/R DLBCL (NCT04438005) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-05-07 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas (NCT04305444) | Zhejiang DTRM Biopharma | 2020-04-24 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (NCT04058470) | Huiqiang Huang | 2020-04-24 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL (NCT04697160) | MorphoSys AG | 2020-04-01 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT04323657) | TCR2 Therapeutics | 2020-03-27 |
| Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL (NCT04354402) | SymBio Pharmaceuticals | 2020-03-26 |
| Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes (NCT04319237) | H. Lee Moffitt Cancer Center and Research Institute | 2020-03-10 |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04182204) | Hoffmann-La Roche | 2020-02-07 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel (NCT05541328) | Novartis Pharmaceuticals | 2020-02-03 |
| R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04214626) | Henan Cancer Hospital | 2020-01-05 |
| Secondary Prognostic Index in RefrActory Lymphoma (NCT04804865) | Weprom | 2020-01-01 |
| Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. (NCT04023916) | Chinese Academy of Medical Sciences | 2019-12-01 |
| CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT04026100) | The First Affiliated Hospital with Nanjing Medical University | 2019-12-01 |
| Study of Out of Specification for Tisagenlecleucel (NCT04094311) | Novartis Pharmaceuticals | 2019-11-21 |
| Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda (NCT03864419) | Fred Hutchinson Cancer Center | 2019-10-24 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (NCT03984448) | National Cancer Institute (NCI) | 2019-10-22 |
| A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT03873025) | University College, London | 2019-10-01 |
| A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04316624) | Institute of Hematology & Blood Diseases Hospital, China | 2019-09-29 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (NCT04104776) | Novartis Pharmaceuticals | 2019-09-18 |
| QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (NCT04052061) | ImmunityBio, Inc. | 2019-09-16 |
| Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) (NCT03990961) | University of Chicago | 2019-09-04 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma (NCT03995147) | University of Chicago | 2019-08-29 |
| ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma (NCT04112238) | Herlev Hospital | 2019-08-29 |
| Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL (NCT03736616) | Swedish Medical Center | 2019-08-16 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (NCT04002947) | National Cancer Institute (NCI) | 2019-08-05 |
| A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL (NCT04361279) | Shanghai Institute Of Biological Products | 2019-07-25 |
| Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment (NCT03677128) | Duke University | 2019-07-23 |
| Biomarker Guided Treatment in DLBCL (NCT04025593) | Ruijin Hospital | 2019-07-17 |
| Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma (NCT03719560) | Brown University | 2019-07-01 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (NCT03960840) | Novartis Pharmaceuticals | 2019-06-26 |
| Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma (NCT03843294) | Catherine Bollard | 2019-06-24 |
| Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies (NCT03955783) | Sanjay Mohan | 2019-06-21 |
| Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients (NCT03876028) | Novartis Pharmaceuticals | 2019-06-11 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma (NCT04089215) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2019-06-11 |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents (NCT03349346) | Gilead Sciences | 2019-06-01 |
| Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma (NCT03939182) | Memorial Sloan Kettering Cancer Center | 2019-05-29 |
| Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (NCT03677154) | Hoffmann-La Roche | 2019-05-23 |
| Lenalidomide Monotherapy in R/R DLBCL (NCT04150328) | MorphoSys AG | 2019-04-12 |
| Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma (NCT03797170) | University of Bologna | 2019-04-02 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT03797261) | AbbVie | 2019-03-18 |
| Early Palliative Care for Patients With Haematological Malignancies (NCT03800095) | University Hospital, Clermont-Ferrand | 2019-03-14 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL (NCT03949062) | Ruijin Hospital | 2019-03-13 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCT03884998) | City of Hope Medical Center | 2019-02-26 |
| Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (NCT03681535) | Duke University | 2019-02-13 |
| Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma (NCT03685344) | ADC Therapeutics S.A. | 2019-02-04 |
| DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma (NCT03837873) | Institute of Hematology & Blood Diseases Hospital, China | 2019-01-21 |
| Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) (NCT03777085) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-01-10 |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies (NCT03999697) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-12-01 |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT03719989) | Seoul National University Hospital | 2018-12-01 |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma (NCT03684694) | ADC Therapeutics S.A. | 2018-12-01 |
| A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (NCT03670901) | JHL Biotech, Inc. | 2018-11-13 |
| Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. (NCT03720457) | Hrain Biotechnology Co., Ltd. | 2018-11-13 |
| A Trial of Radiotherapy and Durvalumab in DLBCL and FL (NCT03610061) | Austin Health | 2018-11-01 |
| Lenalidomide Based Immunotherapy in the Treatment of DLBCL (NCT03715296) | Ruijin Hospital | 2018-10-18 |
| Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (NCT03630159) | Novartis Pharmaceuticals | 2018-10-09 |
| Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma (NCT03656835) | Ohio State University Comprehensive Cancer Center | 2018-09-26 |
| Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma (NCT04833504) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-09-22 |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (NCT03676504) | University Hospital Heidelberg | 2018-09-07 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors (NCT03010982) | Epizyme, Inc. | 2018-06-20 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (NCT03527147) | Acerta Pharma BV | 2018-06-19 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (NCT03543813) | CytomX Therapeutics | 2018-06-15 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (NCT04067414) | Institute of Hematology & Blood Diseases Hospital, China | 2018-06-08 |
| A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma (NCT03579082) | Mingzhi Zhang | 2018-06-01 |
| Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance (NCT03311958) | Fox Chase Cancer Center | 2018-05-15 |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (NCT03530683) | Pfizer | 2018-05-14 |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (NCT03422523) | University Hospital Southampton NHS Foundation Trust | 2018-05-09 |
| Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (NCT03399513) | University Hospital Muenster | 2018-05-03 |
| Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma (NCT03501576) | Emory University | 2018-04-06 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603) | Sutro Biopharma, Inc. | 2018-02-22 |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-19 |
| Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (NCT03276468) | The Lymphoma Academic Research Organisation | 2018-02-12 |
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791) | Novartis Pharmaceuticals | 2018-01-24 |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) (NCT03520920) | BeiGene | 2018-01-04 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (NCT03274492) | Hoffmann-La Roche | 2017-11-16 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL (NCT03019666) | Masonic Cancer Center, University of Minnesota | 2017-10-18 |